Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | USP9X | Q93008 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13249912 | 0.94 | P2RX7 (0.36) | ROCK2CYP3A4P2RX7KMT2A | |
| SCHEMBL13249909 | 0.91 | KCNH2 (0.39) | CYP3A4P2RX7CCR5ALDH1A1TSHR | |
| SCHEMBL13249856 | 0.89 | PTGDR2 (0.38) | ROCK2P2RX7MTHFD2LMNAKMT2A | |
| SCHEMBL13249908 | 0.89 | MTHFD2 (0.33) | P2RX7MTHFD2KMT2ACCR5ALDH1A1 | |
| SCHEMBL13249829 | 0.88 | KMT2A (0.44) | CYP3A4P2RX7LMNAKMT2ACCR5 | |
| SCHEMBL13249922 | 0.88 | KMT2A (0.41) | P2RX7MTHFD2LMNAKMT2ACCR5 | |
| SCHEMBL13249907 | 0.87 | RAB9A (0.37) | P2RX7MTHFD2LMNAKMT2ACCR5 | |
| SCHEMBL13249831 | 0.86 | MTHFD2 (0.46) | P2RX7MTHFD2 | |
| SCHEMBL13249785 | 0.85 | CYP2D6 (0.43) | CYP3A4P2RX7MTHFD2LMNACCR5 | |
| SCHEMBL13249784 | 0.85 | KMT2A (0.47) | CYP3A4P2RX7MTHFD2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | ROCK2 2597/4885CYP3A4 2495/4885P2RX7 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.